Why is glucagon — the 'raise blood sugar' hormone — in a weight-loss drug?

Most people meet glucagon in the context of low blood sugar. An emergency injection of glucagon can save the life of a person in severe hypoglycemia by signaling the liver to dump stored glucose into the bloodstream. So when retatrutide is described as a "triple agonist" that activates the glucagon receptor, the obvious question is: doesn't that do exactly the wrong thing for someone trying to lose weight or manage diabetes?

The published Phase 2 results say no. People on the highest doses lost 24% of body weight on average, with HbA1c either steady or improving in the diabetes trial. [2] The reason comes down to balance.

Glucagon-receptor activation has multiple downstream effects. The classic textbook one is hepatic glucose output: the liver releases stored glycogen, which raises blood sugar. But glucagon also:

• Increases resting energy expenditure. The metabolic rate at rest goes up. The mechanism appears to involve mitochondrial activity in the liver and possibly brown fat.
• Promotes hepatic fat breakdown. Glucagon signaling stimulates beta-oxidation in the liver, mobilizing stored fat. This is why glucagon-class drugs are also being studied for fatty liver disease.
• Slightly suppresses appetite. Independent pathways from GLP-1, but contributing in the same direction.
• Modestly increases sympathetic tone.Which is the mechanistic explanation for retatrutide's small heart-rate signal in trials.

In a vacuum, the glucose-output effect dominates and you get hyperglycemia. With concurrent strong insulin signaling from GLP-1 and GIP, the glucose-output effect is largely offset — and the energy-expenditure and fat-mobilization effects are free to act.

This is why retatrutide's receptor selectivity profile matters so much. Lilly didn't simply build a peptide that activates three receptors equally. The molecule was tuned so that GLP-1 and GIP signaling are potent enough to keep insulin output ahead of the liver's glucose release. [1]

An older drug class — pure glucagon-receptor agonists — was briefly explored decades ago for very different reasons (e.g., emergency hypoglycemia). They reliably raise blood sugar. The combination approach is newer because it required first developing potent enough GLP-1 / GIP agonism to act as a chemical counterweight.

GLP-1 and GIP signaling primarily reduce energy intake — less hunger, slower gastric emptying, more satiety. Adding glucagon to the mix appears to operate on the energy expenditure side of the same balance: same calories in, slightly more calories out.

In retatrutide trials, the additional weight loss compared to tirzepatide cross-trial is roughly 3-4 percentage points at the highest doses. The most plausible explanation for that gap is glucagon-receptor activation — though direct mechanistic proof in humans is still being assembled.

The other thing glucagon does is mobilize hepatic fat, which has independent value for patients with non-alcoholic fatty liver disease (NAFLD) or its more severe form, MASH. This is one reason GLP-1/glucagon combinations like survodutide are being studied specifically for liver disease.

• Heart-rate signal. Retatrutide produced a small dose-dependent increase in resting heart rate of roughly 5-7 bpm at top doses. Survodutide and mazdutide, which also include glucagon agonism, have shown similar signals. The clinical significance is being characterized in larger Phase 3 trials.
• Narrow therapeutic balance. If a future molecule mistuned the glucagon-to-GLP-1 ratio, it could produce hyperglycemia. This is part of why the discovery process for triple agonists is meaningfully harder than for single-receptor drugs.
• Liver effects. Mostly a benefit (fat mobilization), but glucagon also increases urea cycle activity and other liver metabolic pathways. Long-term hepatic effects of chronic glucagon agonism are being studied.
• Mechanism complexity. Adding receptors adds places where individual variation in response can emerge. Phase 3 will reveal whether the glucagon component produces consistent effects across diverse populations.

• Survodutide (Boehringer / Zealand) — GLP-1 / glucagon dual agonist. Phase 2 obesity readout showed ~19% weight loss at 46 weeks. Phase 3 ongoing. [3]
• Mazdutide (Innovent / Lilly) — GLP-1 / glucagon dual. Phase 3 in China. ~15% weight loss reported.
• Cotadutide (AstraZeneca) — GLP-1 / glucagon dual that was discontinued before Phase 3.
• Retatrutide (Lilly) — the only triple agonist (GLP-1 / GIP / glucagon) currently in Phase 3.

The fact that multiple sponsors are pursuing glucagon agonism as a second or third receptor — despite the engineering complexity — is itself evidence that the mechanism is real and meaningful for weight loss and metabolic health.